Schering's new X-ray imaging agent suspended
This article was originally published in Clinica
Schering has temporarily suspended the sale of its X-ray contrast agent, Isovist 280, because of unexpected, delayed allergic skin reactions experienced by users mainly in Japan. Isovist 280 has been introduced in Japan, Germany and Austria since the end of 1994 and the US submission to the FDA had been planned for spring 1996. The latter will be delayed at least a year or two until new clinical trials are completed.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.